Sanofi opened the bidding and drummed up interest in Medivation Inc., but another suitor – Pfizer Inc. – walked off with the prize. While the French pharma may have found the $14bn price tag and the share price premium paid by its US rival too rich for its tastes, it may be able to apply that capital now toward another cancer-focused biotech purchase to bolster its oncology portfolio at a more reasonable cost.
In the days immediately following Pfizer's purchase of Medivation – at $81.50 per share, an estimated 21% premium over a...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

